For locally advanced prostate cancer: - No statistically significant differences in objective response rates, overall survival rates or progression-free survival rates are found between LAs and LAs plus AA combination.
- Findings are based on two studies and should be interpreted with caution.
- There is insufficient evidence to make other comparisons.
For metastatic prostate cancer: - There is a possible advantage in objective response rates when LAs are compared with estrogen therapy, but no overall or progression-free survival advantage is found.
- The combination therapy of LAs with AAs has a potential survival benefit over monotherapy. This advantage varies in magnitude and is not identified for all treatment periods or for all LAs.
These results are based on limited evidence and should be interpreted with caution.